A154 Bortezomib (Velcade)/Melphalan/Prednisone (VMP) Versus Velcade/Thalidomide/Prednisone (VTP) in Elderly

Mateos, M.V.; Martin, M; González, Yolanda; Lahuerta, JJ; Bladé, Joan; Oriol, Albert; Martínez, José Miguel Coleto; Cibeira, MT; Paz, Raquel de; Terol, MJ; García, J. Coullaut-Valera; Bengoechea, Enrique Garcíá; Martínez, Rafael Martínez; Martin, A.; Arriba, Felipe de; Palomera, Luis; Hernandez, JM; Jl, Bello López; Miguel, J San

doi:10.1016/s1557-9190(11)70481-4

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A reduced frequency of administration of bortezomib in combination with MP was investigated in two studies in patients >65 years old. In a trial conducted by the Spanish myeloma group, patients were randomized to receive six cycles of VMP or bortezomib plus thalidomide plus prednisone (VTP) [ 63 ]. During cycle 1 of the induction treatment, bortezomib was administered twice weekly, and in subsequent cycles bortezomib was only administered once weekly.…”

Section: F Ront -L Ine T mentioning

confidence: 99%

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: F Ront -L Ine T mentioning

confidence: 99%

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Table 4[100][101][102][103][104][105][106][107][108][109][110] summarizes data from key studies of novel-agent-based regimens in this setting. A recent analysis of the phase III Velcade as Initial Standard Therapy in Multiple Myeloma; Assessment with Melphalan and Prednisone (VISTA) trial comparing bortezomib plus MP (VMP) with MP demonstrated that achievement of CR versus PR with VMP by EBMT criteria was associated with…”

mentioning

confidence: 99%

Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

Chanan‐Khan

Giralt

2010

JCO

190

122

View full text Add to dashboard Cite

The goal of treatment for multiple myeloma (MM) is to improve patients' long-term outcomes. One important factor that has been associated with prolonged progression-free and overall survival is the quality of response to treatment, particularly achievement of a complete response (CR). There is extensive evidence from clinical studies in the transplant setting in first-line MM demonstrating that CR or maximal response post-transplant is significantly associated with prolonged progression-free and overall survival, with some studies demonstrating a similar association with postinduction response. Supportive evidence is also available from studies in the nontransplant and relapsed settings. With the introduction of bortezomib, thalidomide, and lenalidomide, higher rates of CR are being achieved in both first-line and relapsed MM compared with previous chemotherapeutic approaches, thereby potentially improving long-term outcomes. While standard CR by established response criteria has been shown to have differential prognostic impact compared with lesser responses, increasingly sensitive analytic techniques are now being explored to define more stringent degrees of CR or elimination of minimal residual disease (MRD), including multiparameter flow cytometry and polymerase chain reaction. Demonstrating eradication of MRD by these techniques has already been shown to predict for improved outcomes. Here, we review the prognostic significance of achieving CR in MM and highlight the importance of CR as an increasingly realizable goal at all stages of treatment. We discuss clinical management issues and provide recommendations relevant to practicing oncologists, such as the routine use of sensitive techniques for assessment of disease status to inform evidence-based decisions on optimal patient management.

show abstract

“…In addition, they inhibit angiogenesis and augment natural killer cell activity against autologous MM cells [ 79 – 82 ]. Several clinical trials have demonstrated the benefits of using regimens involving thalidomide or IMiDs (lenalidomide) for MM treatment, particularly in combination with proteasome inhibitors [ 15 , 16 , 63 – 66 , 69 – 71 , 74 , 83 – 96 ]. This combined therapy has become the standard regimen for MM treatment.…”

Section: Current Biological Based Therapies For MMmentioning

confidence: 99%

“…The choice of therapy for patients is influenced by a variety of factors, including age, comorbidities, and eligibility for stem cell transplantation. Treatment strategies for MM patients include two-drug regimens such as bortezomib-dexamethasone [ 62 ], lenalidomide-dexamethasone [ 15 , 16 , 86 , 94 ], or thalidomide-dexamethasone [ 63 , 84 , 92 , 93 ] and three-drug regimens such as bortezomib-thalidomide-dexamethasone [ 63 – 66 ], bortezomib-melphalan-prednisone [ 68 , 69 ], or lenalidomide-bortezomib-dexamethasone (RVD) [ 98 ]. However, RVD has shown the most promising effect.…”

Section: Current Biological Based Therapies For MMmentioning

confidence: 99%

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

Yang

Lin

2015

BioMed Research International

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients eventually relapse or become refractory to current treatments. Although the treatments have improved, the major problem in MM is resistance to therapy. Clonal evolution of MM cells and bone marrow microenvironment changes contribute to drug resistance. Some mechanisms affect both MM cells and microenvironment, including the up- and downregulation of microRNAs and programmed death factor 1 (PD-1)/PD-L1 interaction. Here, we review the pathogenesis of MM cells and bone marrow microenvironment and highlight possible drug resistance mechanisms. We also review a potential molecular targeting treatment and immunotherapy for patients with refractory or relapse MM.

show abstract

A154 Bortezomib (Velcade)/Melphalan/Prednisone (VMP) Versus Velcade/Thalidomide/Prednisone (VTP) in Elderly

Cited by 5 publications

References 0 publications

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

Contact Info

Product

Resources

About